A Longhi

Summary

Affiliation: Istituti Ortopedici Rizzoli
Country: Italy

Publications

  1. ncbi Late effects of chemotherapy and radiotherapy in osteosarcoma and Ewing sarcoma patients: the Italian Sarcoma Group Experience (1983-2006)
    Alessandra Longhi
    Musculoskeletal Department, Chemotherapy Service, Rizzoli Orthopedic Institute, Bologna, Italy
    Cancer 118:5050-9. 2012
  2. ncbi Fibrosarcomatous changes and expression of CD34+ and apolipoprotein-D in dermatofibrosarcoma protuberans
    Emanuela Palmerini
    Chemotherapy, Musculoskeletal Oncology Department, Istituto Ortopedico Rizzoli, Via Pupilli 1, Bologna, 40136, Italy
    Clin Sarcoma Res 2:4. 2012
  3. ncbi Reproductive functions in female patients treated with adjuvant and neoadjuvant chemotherapy for localized osteosarcoma of the extremity
    A Longhi
    Department of Musculoskeletal Oncology Istituto Ortopedico Rizzoli Bologna, Italy
    Cancer 89:1961-5. 2000
  4. ncbi Osteosarcoma in patients older than 65 years
    Alessandra Longhi
    Department of Musculoskeletal Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy
    J Clin Oncol 26:5368-73. 2008
  5. ncbi Twenty-year follow-up of osteosarcoma of the extremity treated with adjuvant chemotherapy
    A Longhi
    Chemotherapy, Department of Musculoskeletal Oncology, Istituti Ortopedici Rizzoli, Bologna, Italy
    J Chemother 16:582-8. 2004
  6. ncbi Simultaneous osteosarcoma lung metastasis and second primary lung cancer
    Alessandra Longhi
    Chemotherapy, Department of Musculoskeletal Oncology, Istituti Ortopedici Rizzoli, Bologna, Italy
    J Pediatr Hematol Oncol 26:457-61. 2004
  7. ncbi Radiation-induced osteosarcoma arising 20 years after the treatment of Ewing's sarcoma
    Alessandra Longhi
    Department of Musculoskeletal Oncology, Rizzoli Orthopedic Institute, Bologna, Italy
    Tumori 89:569-72. 2003
  8. ncbi Neoadjuvant chemotherapy for patients with synchronous multifocal osteosarcoma: results in eleven cases
    A Longhi
    Department of Chemotherapy, Istituto Ortopedico Rizzoli, Bologna, Italy
    J Chemother 13:324-30. 2001
  9. ncbi Fertility in male patients treated with neoadjuvant chemotherapy for osteosarcoma
    Alessandra Longhi
    Department of Musculoskeletal Oncology, Rizzoli Orthopaedic Institute, Bologna, Italy
    J Pediatr Hematol Oncol 25:292-6. 2003
  10. ncbi Aggressive fibromatosis of the neck treated with a combination of chemotherapy and indomethacin
    Alessandra Longhi
    Musculoskeletal Department, Istituto Ortopedico Rizzoli, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136 Bologna, Italy
    Ear Nose Throat J 90:E11-5. 2011

Detail Information

Publications85

  1. ncbi Late effects of chemotherapy and radiotherapy in osteosarcoma and Ewing sarcoma patients: the Italian Sarcoma Group Experience (1983-2006)
    Alessandra Longhi
    Musculoskeletal Department, Chemotherapy Service, Rizzoli Orthopedic Institute, Bologna, Italy
    Cancer 118:5050-9. 2012
    ..Patients with osteosarcoma and Ewing sarcoma have achieved longer survival over the past decades, but late side effects of chemotherapy and radiotherapy have become important concerns...
  2. ncbi Fibrosarcomatous changes and expression of CD34+ and apolipoprotein-D in dermatofibrosarcoma protuberans
    Emanuela Palmerini
    Chemotherapy, Musculoskeletal Oncology Department, Istituto Ortopedico Rizzoli, Via Pupilli 1, Bologna, 40136, Italy
    Clin Sarcoma Res 2:4. 2012
    ..abstract:..
  3. ncbi Reproductive functions in female patients treated with adjuvant and neoadjuvant chemotherapy for localized osteosarcoma of the extremity
    A Longhi
    Department of Musculoskeletal Oncology Istituto Ortopedico Rizzoli Bologna, Italy
    Cancer 89:1961-5. 2000
    ....
  4. ncbi Osteosarcoma in patients older than 65 years
    Alessandra Longhi
    Department of Musculoskeletal Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy
    J Clin Oncol 26:5368-73. 2008
    ..We reviewed the outcome of osteosarcoma patients older than 65 years, an age group usually excluded from protocols, to determine the different clinical features and prognostic factors in this age group compared with younger patients...
  5. ncbi Twenty-year follow-up of osteosarcoma of the extremity treated with adjuvant chemotherapy
    A Longhi
    Chemotherapy, Department of Musculoskeletal Oncology, Istituti Ortopedici Rizzoli, Bologna, Italy
    J Chemother 16:582-8. 2004
    ..Protracted medical follow-up and long-term updated results are useful to identify, at an early stage, late relapses and late treatment-related complications...
  6. ncbi Simultaneous osteosarcoma lung metastasis and second primary lung cancer
    Alessandra Longhi
    Chemotherapy, Department of Musculoskeletal Oncology, Istituti Ortopedici Rizzoli, Bologna, Italy
    J Pediatr Hematol Oncol 26:457-61. 2004
    ..The occurrence of a primitive lung cancer together with lung metastases from osteosarcoma is even more unusual, and examination of all new lung nodules is highly recommended...
  7. ncbi Radiation-induced osteosarcoma arising 20 years after the treatment of Ewing's sarcoma
    Alessandra Longhi
    Department of Musculoskeletal Oncology, Rizzoli Orthopedic Institute, Bologna, Italy
    Tumori 89:569-72. 2003
    ..The patient is alive and free of disease 4 years after the treatment of this second malignant neoplasm (SMN). This case shows that radioinduced SMN can occurr with relatively low doses of RT (<50 Gy) and that it may occur very late...
  8. ncbi Neoadjuvant chemotherapy for patients with synchronous multifocal osteosarcoma: results in eleven cases
    A Longhi
    Department of Chemotherapy, Istituto Ortopedico Rizzoli, Bologna, Italy
    J Chemother 13:324-30. 2001
    ..This homogeneity supports the thesis that in synchronous multifocal osteosarcoma the tumors are not multicentric in origin but represent bone-to-bone metastases from a monocentric tumor...
  9. ncbi Fertility in male patients treated with neoadjuvant chemotherapy for osteosarcoma
    Alessandra Longhi
    Department of Musculoskeletal Oncology, Rizzoli Orthopaedic Institute, Bologna, Italy
    J Pediatr Hematol Oncol 25:292-6. 2003
    ..To evaluate fertility in male patients with osteosarcoma after chemotherapy including high doses of alkylating agents...
  10. ncbi Aggressive fibromatosis of the neck treated with a combination of chemotherapy and indomethacin
    Alessandra Longhi
    Musculoskeletal Department, Istituto Ortopedico Rizzoli, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136 Bologna, Italy
    Ear Nose Throat J 90:E11-5. 2011
    ..We also review the literature on cases of aggressive fibromatosis of the neck that have been reported over the past 12 years...
  11. ncbi Effect of oral contraceptive on ovarian function in young females undergoing neoadjuvant chemotherapy treatment for osteosarcoma
    Alessandra Longhi
    Chemotherapy Service, Rizzoli Orthopaedic Institute, Bologna, Italy
    Oncol Rep 10:151-5. 2003
    ....
  12. ncbi Osteosarcoma in blood relatives
    A Longhi
    Service of Chemotherapy, Istituti Ortopedici Rizzoli, 40136 Bologna, Italy
    Oncol Rep 8:131-6. 2001
    ..These findings confirm that specific genetic alterations occur in osteosarcoma pathogenesis...
  13. ncbi Long-term follow-up of patients with doxorubicin-induced cardiac toxicity after chemotherapy for osteosarcoma
    Alessandra Longhi
    Chemotherapy Division Rizzoli Orthopaedic Institute, St Orsola Malpighi University Hospital, Bologna, Italy
    Anticancer Drugs 18:737-44. 2007
    ..5% and five men=1.1%). Cumulative dose and dose intensity (cumulative dose/week of treatment) are the most important risk factors in developing doxorubicin-related cardiomyopathy...
  14. ncbi Height as a risk factor for osteosarcoma
    Alessandra Longhi
    Chemotherapy Division, Istituto Ortopedico Rizzoli, Via Pupilli 1, Bologna, Italy
    J Pediatr Hematol Oncol 27:314-8. 2005
    ..The higher incidence during the pubertal spurt, in the anatomic sites of greater growth and in taller individuals, suggests that growth factors play an important role in the pathogenesis of this bone cancer...
  15. ncbi Pulmonary nodules in osteosarcoma patients: differential diagnosis of central venous catheter-related infections in the lungs
    A Longhi
    Sezione di Chemioterapia, Dipartimento di Oncologia Muscoloscheletrica, Istituti Ortopedici Rizzoli, Bologna, Italy
    Radiol Med 111:192-201. 2006
    ..The purpose of this study was to evaluate the differential diagnosis of pulmonary nodules by conventional radiography and computed tomography (CT) in osteosarcoma patients with central venous catheter...
  16. ncbi High grade malignant peripheral nerve sheath tumors: outcome of 62 patients with localized disease and review of the literature
    A Longhi
    Musculoskeletal Department, Chemotherapy Division, Istituto Ortopedico Rizzoli, Bologna, Italy
    J Chemother 22:413-8. 2010
    ..New drugs employed successfully in advanced mpNSt should be employed also in the adjuvant setting...
  17. ncbi Primary bone osteosarcoma in the pediatric age: state of the art
    Alessandra Longhi
    Chemotherapy Surgery of the Musculoskeletal, Oncology Department at Rizzoli Orthopaedic Institute, Bologna, Italy
    Cancer Treat Rev 32:423-36. 2006
    ..Other drugs have been employed in relapsed patients with poor results. This article reviews the state of the art of treatment for bone osteosarcoma in the pediatric age...
  18. ncbi Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli
    G Bacci
    Departments of Musculo Skeletal Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy
    J Clin Oncol 18:4-11. 2000
    ..The identification of prognostic factors in patients with nonmetastatic Ewing's sarcoma could allow the use of risk-adapted therapeutic strategies of treatment...
  19. ncbi Local and systemic control for osteosarcoma of the extremity treated with neoadjuvant chemotherapy and limb salvage surgery: the Rizzoli experience
    G Bacci
    Sezione di Chemioterapia, Istituto Ortopedico Rizzoli, 40136 Bologna, Italy
    Oncol Rep 7:1129-33. 2000
    ....
  20. ncbi Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report
    G Bacci
    Service of Chemotherapy, Laboratory of Pathology, Fifth Service of Orthopedic Surgery, and Laboratory of Oncologic Research, Department of Musculoskeletal Oncology, I F Goidanich of the Istituto Ortopedico Rizzoli, Bologna, Italy
    J Clin Oncol 18:4016-27. 2000
    ..To provide an estimate of long-term prognosis for patients with osteosarcoma of the extremity treated in a single institution with neoadjuvant chemotherapy and observed for at least 10 years...
  21. ncbi A comparison of methods of loco-regional chemotherapy combined with systemic chemotherapy as neo-adjuvant treatment of osteosarcoma of the extremity
    G Bacci
    Department of Chemotherapy, Istituto Ortopedico Rizzoli, Bologna, Italy
    Eur J Surg Oncol 27:98-104. 2001
    ..Our experience of pre-operative intraarterial (i.a.) vs intravenous (i.v.) infusion of cisplatinum (CDP) in a multiagent neo-adjuvant chemotherapy for osteosarcoma of the extremity is reported...
  22. ncbi Neoadjuvant chemotherapy for peripheral malignant neuroectodermal tumor of bone: recent experience at the istituto rizzoli
    G Bacci
    Departments of Chemotherapy and Pathology and Fifth Department of Orthopedic Surgery, Istituto Ortopedico Rizzoli, Bologna, Italy
    J Clin Oncol 18:885-92. 2000
    ..The results achieved in 44 patients with nonmetastatic peripheral neuroectodermal tumor (PNET) of bone treated with neoadjuvant chemotherapy are reported...
  23. ncbi Neoadjuvant chemotherapy for extremity osteosarcoma--preliminary results of the Rizzoli's 4th study
    G Bacci
    Department of Chemotherapy, Istituto Ortopedico Rizzoli, Bologna, Italy
    Acta Oncol 37:41-8. 1998
    ..Therefore, until new effective drugs are found, expertise in using the four known drugs may improve cure rate and help to avoid amputation in almost all patients...
  24. ncbi Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide
    G Bacci
    Section of Chemotherapy, Department of Musculoskeletal Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy
    Ann Oncol 14:1126-34. 2003
    ..Currently, little is known about patients with metastatic disease at presentation...
  25. ncbi Neoadjuvant chemotherapy for high grade osteosarcoma of the extremities: long-term results for patients treated according to the Rizzoli IOR/OS-3b protocol
    G Bacci
    Chemotherapy Division, Istituto Ortopedico Rizzoli, Bologna, Italy
    J Chemother 13:93-9. 2001
    ..These results, however, are no better than those achieved in our previous study IOR/OS-3a, in which only poor responder patients received ifosfamide during the postoperative treatment...
  26. ncbi High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study
    G Bacci
    Sezione di Chemioterapia, Instituto Ortopedico Rizzoli, Bologna, Italy
    J Chemother 14:198-206. 2002
    ..On the basis of this study, in March 1997 the Italian and Scandinavian Sarcoma Groups started a new protocol for osteosarcoma of the extremities...
  27. ncbi Relationship between dose-intensity of treatment and outcome for patients with osteosarcoma of the extremity treated with neoadjuvant chemotherapy
    G Bacci
    Service of Chemotherapy, Istituto Ortopedico Rizzoli, Via Pupilli 1, I 40136 Bologna, Italy
    Oncol Rep 8:883-8. 2001
    ....
  28. ncbi Predictive factors of histological response to primary chemotherapy in Ewing's sarcoma
    G Bacci
    Department of Musculoskeletal Oncology, Istituti Ortopedici Rizzoli, Bologna, Italy
    Acta Oncol 37:671-6. 1998
    ..The analysis of event-free survival in 158 patients with a 4-year minimum follow-up confirmed that histological response to preoperative chemotherapy is a reliable predictor of outcome in Ewing's sarcoma...
  29. ncbi Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli's 4th protocol
    G Bacci
    Department of Chemotherapy, Istituto Ortopedico Rizzoli, Bologna, Italy
    Eur J Cancer 37:2030-9. 2001
    ..These results did not differ from those achieved in our previous study (IOR/OS-3) in which IFO was used only postoperatively in poor responders...
  30. ncbi Pattern of relapse in patients with osteosarcoma of the extremities treated with neoadjuvant chemotherapy
    G Bacci
    Service of Chemotherapy, Rizzoli Orthopedic Institute, Via Pupilli, 40136, Bologna, Italy
    Eur J Cancer 37:32-8. 2001
    ....
  31. ncbi Long-term outcome for patients with non-metastatic Ewing's sarcoma treated with adjuvant and neoadjuvant chemotherapies. 402 patients treated at Rizzoli between 1972 and 1992
    G Bacci
    Sezione di Chemioterapia, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136 Bologna, Italy
    Eur J Cancer 40:73-83. 2004
    ..We conclude that since local or systemic relapses, treatment-complications and second malignancies are more common after 5 years or more from the beginning of treatment; a long-term follow-up is mandatory for patients with ES...
  32. ncbi Therapy and survival after recurrence of Ewing's tumors: the Rizzoli experience in 195 patients treated with adjuvant and neoadjuvant chemotherapy from 1979 to 1997
    G Bacci
    Department of Chemotherapy, Istituto Ortopedico Rizzoli, Bologna, Italy
    Ann Oncol 14:1654-9. 2003
    ..Many papers have reported the results achieved with combined therapy for Ewing's tumors, but little is known about the treatment and outcome of those 30-40% of patients who relapse...
  33. ncbi Telangiectatic osteosarcoma of the extremity: neoadjuvant chemotherapy in 24 cases
    G Bacci
    Department of Chemotherapy, Istituto Ortopedico Rizzoli, Bologna, Italy
    Acta Orthop Scand 72:167-72. 2001
    ..01) in the TO group. We conclude that TO, once considered a lethal tumor, seems to be even more sensitive to chemotherapy than conventional osteosarcoma, and that most of these patients may be cured without amputation...
  34. ncbi Pattern of relapse in 290 patients with nonmetastatic Ewing's sarcoma family tumors treated at a single institution with adjuvant and neoadjuvant chemotherapy between 1972 and 1999
    G Bacci
    Section of Chemotherapy, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136 Bologna, Italy
    Eur J Surg Oncol 32:974-9. 2006
    ..Evaluation of pattern of recurrences of 290 patients with an Ewing's sarcoma family tumor (ESFT), who relapsed after adjuvant or neoadjuvant chemotherapy...
  35. ncbi Adjuvant and neo-adjuvant chemotherapy for Ewing's sarcoma family tumors and osteosarcoma of the extremity: further outcome for patients event-free survivors 5 years from the beginning of treatment
    G Bacci
    Section of Chemotherapy, Istituto Ortopedico Rizzoli, Bologna, Italy
    Ann Oncol 18:2037-40. 2007
    ..Post 5-year follow-up for these patients was 9.7 years (5.5-29 years)...
  36. ncbi Local and systemic control in Ewing's sarcoma of the femur treated with chemotherapy, and locally by radiotherapy and/or surgery
    G Bacci
    Department of Chemotherapy, Istituto Ortopedico Rizzoli, Bologna, Italy
    J Bone Joint Surg Br 85:107-14. 2003
    ..Further studies are needed to verify the impact of this strategy on overall survival...
  37. ncbi Neoadjuvant chemotherapy for Ewing's sarcoma of bone in patients older than thirty-nine years
    G Bacci
    Department of Chemotherapy, Istituto Ortopedico Rizzoli, Bologna, Italy
    Acta Oncol 39:111-6. 2000
    ..We conclude that Ewing's sarcoma of bone in adults is no different from that occurring in children, and we therefore recommend the inclusion of all adult patients in multidisciplinary treatment trials of this tumor...
  38. ncbi Sex- and age-related chemotherapy toxicity in patients with non-metastatic osteosarcoma
    S Ferrari
    Chemotherapy Unit, Instituto Ortopedico Rizzoli, Bologna, Italy
    J Chemother 21:205-10. 2009
    ..further investigations on sex-related susceptibility to chemotherapy in osteosarcoma patients are recommended...
  39. ncbi Ifosfamide and actinomycin-D, added in the induction phase to vincristine, cyclophosphamide and doxorubicin, improve histologic response and prognosis in patients with non metastatic Ewing's sarcoma of the extremity
    S Ferrari
    Department of Chemotherapy, Istituto Ortopedico Rizzoli Bologna, Italy
    J Chemother 10:484-91. 1998
    ..The present study suggests the importance of early use of ifosfamide in the treatment of patients with non metastatic Ewing's sarcoma of the extremity...
  40. ncbi Neoadjuvant chemotherapy for the treatment of osteosarcoma of the extremities: a comparison of results obtained in single-institution and multicenter trials
    G Bacci
    Dipartimento di Oncologia Muscoloscheletrica, Istituti Ortopedici Rizzoli, Bologna, Italia
    Chir Organi Mov 89:283-92. 2004
    ..Based on these differences, the authors conclude that it would be opportune to direct patients with osteosarcoma of the extremities to the best centers that each year treat large numbers of patients with musculoskeletal tumors...
  41. ncbi Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: an analysis of 300 patients treated at the Rizzoli Institute
    S Ferrari
    Chemotherapy, Istituti Ortopedici Rizzoli, Bologna, Italy
    Ann Oncol 12:1145-50. 2001
    ..To identify predictive factors of disease-free survival (DFS) in patients with non-metastatic osteosarcoma of the extremity, treated with primary chemotherapy and delayed surgery...
  42. ncbi Neoadjuvant chemotherapy for Ewing's tumour of bone: recent experience at the Rizzoli Orthopaedic Institute
    G Bacci
    Section of Chemotherapy, Rizzoli Orthopaedic Institute, Bologna, Italy
    Eur J Cancer 38:2243-51. 2002
    ....
  43. ncbi Osteosarcoma of the limb. Amputation or limb salvage in patients treated by neoadjuvant chemotherapy
    G Bacci
    Department of Chemotherapy, Rizzoli Orthopaedic Institute, Bologna, Italy
    J Bone Joint Surg Br 84:88-92. 2002
  44. ncbi Delay in diagnosis of high-grade osteosarcoma of the extremities. Has it any effect on the stage of disease?
    G Bacci
    Department of Musculoskeletal Oncology, Istituti Ortopedici Rizzoli, Bologna, Italy
    Tumori 86:204-6. 2000
    ....
  45. ncbi Ewing's sarcoma family tumours. Differences in clinicopathological characteristics at presentation between localised and metastatic tumours
    G Bacci
    Istituti Ortopedici Rizzoli, Via Pupilli 1, 40136 Bologna, Italy
    J Bone Joint Surg Br 89:1229-33. 2007
    ..We concluded that in ESFT the site, the serum level of lactic dehydrogenase, fever, and the interval between the onset of symptoms and diagnosis are indicators of tumours having a particularly aggressive metastatic behaviour...
  46. ncbi Brain tumors as second malignant neoplasms in patients with osteosarcoma treated with adjuvant and neoadjuvant chemotherapy: report of 2 cases
    A Longhi
    Department of Musculo Skeletal Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy
    J Chemother 12:261-2. 2000
    ..They developed the brain tumor (one astrocytoma and one glioblastoma) 3 and 5 yr after treatment, (chemotherapy and surgery), for localized osteosarcoma of the extremity...
  47. ncbi Nonmetastatic osteosarcoma of the extremity: results of a neoadjuvant chemotherapy protocol (IOR/OS-3) with high-dose methotrexate, intraarterial or intravenous cisplatin, doxorubicin, and salvage chemotherapy based on histologic tumor response
    S Ferrari
    Chemioterapia, I Clinica Ortopedica dell Università di Bologna, Italy
    Tumori 85:458-64. 1999
    ..Additional aims were to assess the role of the route of infusion (intraarterial or intravenous) of cisplatin on histologic response of the primary tumor and the use of ifosfamide as salvage chemotherapy in poor responders...
  48. ncbi Neoadjuvant chemotherapy for radioinduced osteosarcoma of the extremity: The Rizzoli experience in 20 cases
    Gaetano Bacci
    Sections of Chemotherapy, Istituti Ortopedici Rizzoli, Bologna, Italy
    Int J Radiat Oncol Biol Phys 67:505-11. 2007
    ..Evaluate treatment and outcome of 20 patients with radioinduced osteosarcoma (RIO). Because of previous primary tumor treatment, RIO protocols were different from others we used for non-RIO...
  49. ncbi Second malignant neoplasm in patients with osteosarcoma of the extremities treated with adjuvant and neoadjuvant chemotherapy
    Gaetano Bacci
    Chemotherapy, Department of Musculoskeletal Oncology, Istituti Ortopedici Rizzoli, Bologna, Italy
    J Pediatr Hematol Oncol 28:774-80. 2006
    ..0.8%, P<0.009). Our study showed that the risk of second neoplasm within 15 years increased and then leveled off and that although secondary solid tumors could be explained as unrelated cases, leukemias seem to be over represented...
  50. ncbi Adjuvant and neoadjuvant chemotherapy for Ewing sarcoma family tumors in patients aged between 40 and 60: report of 35 cases and comparison of results with 586 younger patients treated with the same protocols in the same years
    Gaetano Bacci
    Department of Chemotherapy, Rizzoli Orthopaedic Institute, Bologna, Italy
    Cancer 109:780-6. 2007
    ..The clinical and pathologic features of 46 patients 40 to 60 years old with Ewing sarcoma family tumor (ESFT) diagnosed at the authors' institute between 1972 and 2000 were reviewed...
  51. ncbi Bone metastases in osteosarcoma patients treated with neoadjuvant or adjuvant chemotherapy: the Rizzoli experience in 52 patients
    Gaetano Bacci
    Section of Chemotherapy, Department of Musculoskeletal Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy
    Acta Orthop 77:938-43. 2006
    ....
  52. ncbi Non-metastatic osteosarcoma of the extremities in children aged 5 years or younger
    Massimo Eraldo Abate
    Department of Chemotherapy, Istituto Ortopedico Rizzoli, Bologna, Italy
    Pediatr Blood Cancer 55:652-4. 2010
    ..The occurrence of high-grade osteosarcoma is rare in children aged 5 years or younger and only limited series or case reports have been described...
  53. ncbi Vincristine, doxorubicin, cyclophosfamide, actinomycin D, ifosfamide, and etoposide in adult and pediatric patients with nonmetastatic Ewing sarcoma. Final results of a monoinstitutional study
    Stefano Ferrari
    Chemotherapy, Istituto Ortopedico Rizzoli, Bologna, Italy
    Tumori 96:213-8. 2010
    ..To investigate a six-drug combination in patients with nonmetastatic Ewing sarcoma, focusing on chemotherapy-induced necrosis and chemotherapy toxicity in adult and pediatric patients...
  54. ncbi Giant cell tumor of the extremity: A review of 349 cases from a single institution
    Costantino Errani
    Musculoskeletal Oncology Department, Istituto Ortopedico Rizzoli, Bologna, Italy
    Cancer Treat Rev 36:1-7. 2010
    ..Special attention must be given to giant cell tumors not only in the distal radius, but also in the proximal femur, where the treatment is more difficult and associated with a higher rate of local recurrence...
  55. ncbi Local recurrence and local control of non-metastatic osteosarcoma of the extremities: a 27-year experience in a single institution
    Gaetano Bacci
    Chemotherapy, Department of Musculoskeletal Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy
    J Surg Oncol 96:118-23. 2007
    ..Indications and contraindications for limb salvage versus amputation for local treatment of osteosarcoma of the extremity are still controversial...
  56. ncbi Neoadjuvant chemotherapy for osteosarcoma of the extremities in patients aged 41-60 years: outcome in 34 cases treated with adriamycin, cisplatinum and ifosfamide between 1984 and 1999
    Gaetano Bacci
    Section of Chemotherapy, Department of Musculoskeletal Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy
    Acta Orthop 78:377-84. 2007
    ....
  57. ncbi Treatment of nonmetastatic Ewing's sarcoma family tumors of the spine and sacrum: the experience from a single institution
    Gaetano Bacci
    Sezione di Chemioterapia, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy
    Eur Spine J 18:1091-5. 2009
    ..We concluded that regardless of the type of local treatment even when associated with neoadjuvant therapy, ESFT in the spine and sacrum has a poor outcome and prognosis is significantly worse than that of primary ESFT in other sites...
  58. ncbi Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma
    Sofia Avnet
    Laboratory for Pathophysiology, Rizzoli Orthopaedic Institute, Bologna, Italy
    Cancer Res 69:2443-52. 2009
    ..Cotargeting IGFIR and IR-A is more effective than targeting IGF-IR alone in inhibiting OS growth...
  59. ncbi Increased osteoclast activity is associated with aggressiveness of osteosarcoma
    Sofia Avnet
    Laboratory for Pathophysiology, Istituti Ortopedici Rizzoli, 40136 Bologna, Italy
    Int J Oncol 33:1231-8. 2008
    ..0117). In conclusion, tumor-infiltrating osteoclasts are frequently found in OS and increased serum TRACP 5b levels and the presence of active osteoclast at primary sites were positively associated with tumor aggressiveness...
  60. ncbi Spontaneous regression of lung metastasis from osteosarcoma: a case report
    Gaetano Bacci
    Division of Chemotherapy, Istituto Ortopedico Rizzoli, Bologna, Italy
    J Pediatr Hematol Oncol 30:90-2. 2008
    ..The patient was followed up every 3 months and a spontaneous regression of the lesion was documented. Seven years after the diagnosis of lung metastases, no pulmonary nodules or other signs of relapse are present...
  61. ncbi Predictive factors of histologic response to primary chemotherapy in patients with Ewing sarcoma
    Stefano Ferrari
    Chemotherapy, Department of Musculoskeletal Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy
    J Pediatr Hematol Oncol 29:364-8. 2007
    ..003). Female were more likely to achieve a GR (F 64% vs. M 42%, P<0.02). After multivariate analysis sex and age retained statistical significance. Age and sex influence the histologic response in patients with Ewing sarcoma...
  62. ncbi Late relapse in osteosarcoma
    Stefano Ferrari
    Chemotherapy of the Department of Musculoskeletal Oncology at Istituti Ortopedici Rizzoli, Bologna, Italy
    J Pediatr Hematol Oncol 28:418-22. 2006
    ..No clinical predictive factors of late relapse were identified and a prolonged follow-up is recommended for all patients...
  63. ncbi Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution
    Gaetano Bacci
    Department of Chemotherapy, Istituto Ortopedico Rizzoli, Bologna, Italy
    Cancer 106:1154-61. 2006
    ..The evaluation variables influencing systemic and local recurrence and final outcome are extremely important in defining risk-adapted treatments for patients with nonmetastatic osteosarcoma of the extremity...
  64. ncbi Prognostic significance of serum lactate dehydrogenase in osteosarcoma of the extremity: experience at Rizzoli on 1421 patients treated over the last 30 years
    Gaetano Bacci
    Chemotherapy, Department of Musculoskeletal Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy
    Tumori 90:478-84. 2004
    ..The study evaluated the correlation between pretreatment serum lactate dehydrogenase (LDH) levels with the stage of disease and its clinical prognostic value...
  65. ncbi Role of surgery in local treatment of Ewing's sarcoma of the extremities in patients undergoing adjuvant and neoadjuvant chemotherapy
    Gaetano Bacci
    Section of Chemotherapy, Istituto Ortopedico Rizzoli, Via Pupilli 1, I 40136 Bologna, Italy
    Oncol Rep 11:111-20. 2004
    ..Our results indicate that surgery should always be considered in the local treatment of ES of the extremities. Postoperative radiation therapy must be added in case of inadequate surgical margins...
  66. ncbi Neoadjuvant chemotherapy for osteosarcoma of the extremity: intensification of preoperative treatment does not increase the rate of good histologic response to the primary tumor or improve the final outcome
    Gaetano Bacci
    Chemotherapy, Department of Musculoskeletal Oncology, Istituto Ortopedico Rizzolo, Bologna, Italy
    J Pediatr Hematol Oncol 25:845-53. 2003
    ....
  67. ncbi Nonmetastatic osteosarcoma of the extremity with pathologic fracture at presentation: local and systemic control by amputation or limb salvage after preoperative chemotherapy
    Gaetano Bacci
    Department of Musculoskeletal Oncology of the Rizzoli Orthopaedic Institute, Bologna, Italy
    Acta Orthop Scand 74:449-54. 2003
    ....
  68. ncbi Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy
    Gaetano Bacci
    Department of Musculoskeletal Oncology, Division of Chemotherapy, Istituto Ortopedico Rizzoli, Via Pupilli 1, I 40136 Bologna, Italy
    Oncol Rep 10:851-7. 2003
    ..However, if "rescue" treatment is started early, the consequent morbility is tolerable and these patients can be rescued using only HDLV, without the need for extracorporeal removal...
  69. ncbi Neoadjuvant chemotherapy for high-grade central osteosarcoma of the extremity. Histologic response to preoperative chemotherapy correlates with histologic subtype of the tumor
    Gaetano Bacci
    Department of Musculoskeletal Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy
    Cancer 97:3068-75. 2003
    ..In primary central high-grade osteosarcoma, a number of distinct subtypes have been identified, but little is known about the response to chemotherapy...
  70. ncbi Multimodal therapy for the treatment of nonmetastatic Ewing sarcoma of pelvis
    Gaetano Bacci
    Chemotherapy Unit, Department of Musculoskeletal Oncology of the Rizzoli Orthopedic Institute, Bologna, Italy
    J Pediatr Hematol Oncol 25:118-24. 2003
    ..64% and 44% vs. 69%). Thus, despite associated chemotherapy, the outcome of ES localized in the pelvis remains poor, and new innovative methods for the treatment of this tumor are needed...
  71. ncbi High-grade osteosarcoma of the extremity: differences between localized and metastatic tumors at presentation
    Gaetano Bacci
    Department of Chemotherapy, Rizzoli Orthopedic Institute, Bologna, Italy
    J Pediatr Hematol Oncol 24:27-30. 2002
    ....
  72. ncbi Primary high-grade osteosarcoma: comparison between preadolescent and older patients
    Gaetano Bacci
    Department of Chemotherapy, Istituti Ortopedici Rizzoli, Bologna, Italy
    J Pediatr Hematol Oncol 27:129-34. 2005
    ..89%), and good histologic response to preoperative treatment (65% vs. 63%) were essentially the same. The authors concluded that there is no need to employ different therapies for the two groups...
  73. ncbi Grade of chemotherapy-induced necrosis as a predictor of local and systemic control in 881 patients with non-metastatic osteosarcoma of the extremities treated with neoadjuvant chemotherapy in a single institution
    Gaetano Bacci
    Chemotherapy, Department of Musculoskeletal Oncology, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136 Bologna, Italy
    Eur J Cancer 41:2079-85. 2005
    ..Nonetheless, since they represent more than 70% of all osteosarcomas, we conclude that chemotherapy-induced necrosis has a significant prognostic value, regardless of the type of chemotherapy performed after surgery...
  74. ncbi Prognostic factors in non-metastatic Ewing's sarcoma tumor of bone: an analysis of 579 patients treated at a single institution with adjuvant or neoadjuvant chemotherapy between 1972 and 1998
    Gaetano Bacci
    Chemotherapy, Musculoskeletal Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy
    Acta Oncol 45:469-75. 2006
    ..Criteria to stratify patients according to the risk of local or systemic relapse should not be based on a single prognostic factor, but should include all the variables that showed prognostic significance...
  75. ncbi Influence of local recurrence on survival in patients with extremity osteosarcoma treated with neoadjuvant chemotherapy: the experience of a single institution with 44 patients
    Gaetano Bacci
    Division of Chemotherapy, Institute Ortopedico Rizzoli, Bologna, Italy
    Cancer 106:2701-6. 2006
    ....
  76. ncbi The role of surgical margins in treatment of Ewing's sarcoma family tumors: experience of a single institution with 512 patients treated with adjuvant and neoadjuvant chemotherapy
    Gaetano Bacci
    Section of Chemotherapy, Department of Musculoskeletal Oncology, Istituti Ortopedici Rizzoli, Bologna, Italy
    Int J Radiat Oncol Biol Phys 65:766-72. 2006
    ..To evaluate the importance of surgical margins for local and systemic control of Ewing's sarcoma family tumors (ESFT)...
  77. ncbi No correlation between methotrexate serum level and histologic response in the pre-operative treatment of extremity osteosarcoma
    Gaetano Bacci
    Chemotherapy Research of the Department of Musculoskeletal Oncology, Istituti Ortopedici Rizzoli, Bologna, Italy
    Anticancer Drugs 17:411-5. 2006
    ..Thus, increasing the dose of MTX increases the MTX serum peaks, but does not correlate with the histologic response of the tumor...
  78. ncbi Prognostic significance of serum alkaline phosphatase in osteosarcoma of the extremity treated with neoadjuvant chemotherapy: recent experience at Rizzoli Institute
    Gaetano Bacci
    Sezione di Chemioterapia, Istituti Ortopedici Rizzoli, I 40136 Bologna, Italy
    Oncol Rep 9:171-5. 2002
    ....
  79. ncbi Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 year experience at Rizzoli Institute, Italy
    Gaetano Bacci
    Department of Musculoskeletal Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy
    Eur J Cancer 41:2836-45. 2005
    ..However, since local or systemic relapses, myocardiopathies and a second malignancy are possible even 5 or more years since the beginning of treatment, a long-term follow-up is recommended...
  80. ncbi Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups
    Stefano Ferrari
    Chemotherapy Division of Department of Musculoskeletal Oncology, Istituti Ortopedici Rizzoli, Via C Pupilli 1, 40136 Bologna, Italy
    J Clin Oncol 23:8845-52. 2005
    ..To explore the effect of high-dose ifosfamide in first-line treatment for patients < or = 40 years of age with nonmetastatic osteosarcoma of the extremity...
  81. ncbi Treatment and outcome of recurrent osteosarcoma: experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy
    Gaetano Bacci
    Section of Chemotherapy, Department of Musculoskeletal Oncology, Istituto Ortopedico, Rizzoli, Bologna, Italy
    Acta Oncol 44:748-55. 2005
    ..The complete removal of the recurrence is essential for outcome, while the role of the association of second-line chemotherapy remains to be defined...
  82. ncbi Second malignancy in 597 patients with ewing sarcoma of bone treated at a single institution with adjuvant and neoadjuvant chemotherapy between 1972 and 1999
    Gaetano Bacci
    Department of Chemotherapy, Musculoskeletal Oncology at Istituto Ortopedico Rizzoli, Bologna, Italy
    J Pediatr Hematol Oncol 27:517-20. 2005
    ..Based on this, postoperative radiotherapy should be avoided when surgery with adequate margins is feasible...
  83. ncbi Ewing's sarcoma family tumors of the humerus: outcome of patients treated with radiotherapy, surgery or surgery and adjuvant radiotherapy
    Gaetano Bacci
    Department of Chemotherapy, Istituto Ortopedico Rizzoli, Bologna, Italy
    Radiother Oncol 93:383-7. 2009
    ..Local treatment for non-metastatic Ewing's sarcoma family tumors (ESFTs) is controversial. Results achieved in a single institution in patients with ESFT of the humerus are presented...
  84. ncbi Maternal and neonatal outcomes in pregnancies complicated by bone and soft-tissue tumors
    Alessandra Longhi
    Obstet Gynecol 105:447; author reply 447-8. 2005
  85. ncbi A comment and update on "Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival?"
    Gaetano Bacci
    Eur J Cancer 39:548-9. 2003